Mersana Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference
03 mai 2023 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Host First Quarter 2023 Conference Call on May 9, 2023
02 mai 2023 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting
26 avr. 2023 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 avr. 2023 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial
13 mars 2023 07h30 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Provides Statement About SVB
10 mars 2023 19h10 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 mars 2023 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results
28 févr. 2023 07h00 HE
|
Mersana Therapeutics, Inc.
Commenced dose expansion portion of Phase 1 UPGRADE-A clinical trial of UpRi in combination with carboplatinInitiated patient dosing in Phase 1 clinical trial of lead Immunosynthen ADC candidate,...
Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023
21 févr. 2023 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 févr. 2023 16h05 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...